HB 774 would revise Montana drug and insurance laws to prevent nonopioid pain medications from being treated less favorably than opioid or narcotic pain medications on Medicaid and commercial insurance formularies. The bill directs the Department of Public Health and Human Services, when maintaining Medicaid’s formulary and preferred drug list, to ensure FDA-approved nonopioid pain drugs are not disadvantaged or discouraged through preferred/nonpreferred status, prior authorization, step therapy, or other utilization controls more restrictive than those applied to opioid or narcotic alternatives.
The bill also extends similar requirements to commercial insurance policies, certificates, contracts, and certain self-funded employee benefit plans, to the extent not preempted by federal law. Under the bill, if coverage restrictions are placed on a nonopioid pain drug, the prescribing provider must be allowed an exception when the provider determines the drug is appropriate for the patient. The bill further requires public website posting of prescription drug benefit and formulary information and ties the new requirements into existing insurance and Medicaid statutory frameworks by amending several sections of the Montana Code Annotated.
Impact
HB 774 would add new statutory protections for nonopioid pain medications within Medicaid and commercial insurance coverage rules, while also modifying existing provisions governing health maintenance organizations, utilization review organizations, self-funded multiple employer welfare arrangements, and Medicaid drug purchasing/program administration. In practice, it would limit insurers and the state Medicaid program from using formulary placement, cost-sharing tiers, prior authorization, or step therapy in ways that place nonopioid pain drugs at a disadvantage relative to opioid or narcotic pain drugs. It also requires more transparency by mandating public access to formulary and prescription drug benefit information and by requiring notice before utilization review changes are implemented.
Sentiment
The bill’s stated purpose and structure indicate generally favorable policy intent toward expanding access to nonopioid pain treatment and reducing barriers that may steer patients toward opioids. The bill text emphasizes combating opioid addiction and overdose by improving access to alternatives, suggesting support for a public health approach to pain management. No committee transcript or vote record is provided, and the bill was ultimately withdrawn under House Rule H30-50(3)(b), so there is no recorded floor vote sentiment in the materials provided.
Contention
The main points of contention are likely to be the bill’s limits on insurer and Medicaid formulary management, especially where those limits could reduce the ability of plans to use preferred drug lists, utilization management, or tiered cost-sharing to control costs. Another likely issue is the bill’s application to self-funded employee benefit plans only “to the extent not preempted by federal law,” which signals potential ERISA preemption concerns. The bill also preserves some flexibility by allowing one nonopioid to be preferred over another and one opioid over another, but it restricts differential treatment between opioid and nonopioid pain drugs, which may be viewed as a significant mandate by payers and plan administrators.